Holen Sie sich die Stockscreener-App
21.25
0.07%
0.0882
Schlusskurs vom Vortag:
$21.34
Offen:
$21.16
24-Stunden-Volumen:
44,129
Relative Volume:
0.06
Marktkapitalisierung:
$1.54B
Einnahmen:
$434.49M
Nettoeinkommen (Verlust:
$504.34M
KGV:
3.5338
EPS:
6.0138
Netto-Cashflow:
$181.97M
1W Leistung:
+0.02%
1M Leistung:
+4.12%
6M Leistung:
-4.32%
1J Leistung:
+5.82%
1-Tages-Spanne:
$21.13
$21.41
1-Wochen-Bereich:
$20.87
$21.51
52-Wochen-Spanne:
$16.52
$25.14
Innoviva Inc Stock (INVA) Company Profile
Firmenname
Innoviva Inc
Sektor
Branche
Telefon
(650) 238-9600
Adresse
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
21.26 | 1.54B | 434.49M | 504.34M | 181.97M | 6.0138 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Eingeleitet | BTIG Research | Buy |
| 2025-09-30 | Eingeleitet | Goldman | Sell |
| 2025-08-11 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-20 | Eingeleitet | Goldman | Neutral |
| 2017-11-20 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Innoviva Inc Aktie (INVA) Neueste Nachrichten
Innoviva to Participate in Upcoming September 2026 Investor Conferences - biospace.com
Innoviva to Participate in Upcoming Investor Conferences - Yahoo Finance
INVA Q2 2026 Earnings: EPS Misses by 356% as Loss Hits $1.14Consensus Forecast Report - vinanet.vn
(INVA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Entasis Therapeutics Holdings Inc. (ETTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Innoviva CEO Pavel Raifeld Executes Tax-Related Share Withholding Transaction - Kalkine Media
Innoviva CFO Stephen Basso Reports Share Withholding Transaction to Cover Taxes on August 2026 Equity Vesting - Kalkine Media
Cantor Fitzgerald reiterates Innoviva stock rating at overweight By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Innoviva stock rating at overweight - Investing.com
NewEdge Wealth LLC Acquires New Stake in Innoviva, Inc. $INVA - MarketBeat
Innoviva, Inc. (NASDAQ:INVA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Innoviva (INVA) Snapshot: Posts a 2.23% Loss to $21.00 in Latest Trading; the Session Ends Within the Reported Technical Boundaries on the DayWedge Breakout - vinanet.vn
70,000 Shares in Innoviva, Inc. $INVA Purchased by Chase Investment Counsel Corp - MarketBeat
Innoviva’s Earnings Swing And Buyback Might Change The Case For Investing In Innoviva (INVA) - simplywall.st
Innoviva, Inc.: Target Price Consensus and Analysts Recommendations | INVA | US45781M1018 - marketscreener.com
Bank of America Corp DE Has $37.75 Million Stake in Innoviva, Inc. $INVA - MarketBeat
Innoviva (INVA) Holds Near $20.87 After Modest 0.29% GainSuperTrend - vinanet.vn
Innoviva, Inc. (INVA) Stock Forecasts - Yahoo! Finance Canada
Innoviva (INVA) Holds Near $20.81 as Biopharma Royalty Stock Stays RangeboundVolatility Smile - vinanet.vn
HC Wainwright Issues Positive Forecast for Innoviva Earnings - MarketBeat
Three Innoviva therapies named finalists for Prix Galien award By Investing.com - Investing.com Australia
Three Innoviva therapies named finalists for Prix Galien award - Investing.com
Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award - Business Wire
Innoviva, Inc. (INVA) Stock Analysis: Uncovering a 69% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
How (INVA) Movements Inform Risk Allocation Models - Stock Traders Daily
Innoviva (INVA) Holds Steady at $20.68: Key Support and Resistance in FocusParabolic SAR - dars.gov.et
Does Innoviva’s Q2 Loss and Buyback-Fueled EPS Shift Change The Bull Case For INVA? - webull.com
Innoviva stock price target reiterated at $46 by H.C. Wainwright - Investing.com Nigeria
Innoviva Stock Price Forecast. Should You Buy INVA? - StockInvest.us
Innoviva Inc (INVA) Stock News Today - TradingKey
How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors - Yahoo Finance
Innoviva Inc (INVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cantor Fitzgerald Maintains Innoviva(INVA.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Innoviva (INVA) Stock Can Revenue Growth Offset A Sharp Profit Reversal - webull.com
Cantor Fitzgerald Lowers Innoviva (NASDAQ:INVA) Price Target to $34.00 - MarketBeat
Innoviva (INVA) Slips 2.2% as Shares Approach Key Support at $19.61Stock Picks - dars.gov.et
Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic (NASDAQ:INVA) - Seeking Alpha
BTIG Maintains Innoviva(INVA.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Innoviva (NASDAQ:INVA) Announces Quarterly Earnings Results, Misses Expectations By $1.58 EPS - MarketBeat
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress - BioSpace
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Innoviva: Q2 Earnings Snapshot - Barchart.com
Innoviva, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Innoviva, Inc. Q2 2026: Revenue $119.6M, EPS $(1.14) — 10-Q Summary - tradingview.com
Innoviva reports Q2 2026 revenue $119.6M, net loss $83.4M on investment markdowns - TradingView
Earnings Flash (INVA) Innoviva, Inc. Reports Q2 Revenue $119.6M, vs. FactSet Est of $111.0M - marketscreener.com
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 5, 2025. - marketscreener.com
BRIEF-Innoviva Q2 Royalty Revenue USD 56.334 Million - TradingView
Innoviva reports $119.6 million Q2 revenue and $83.4 million net loss - Quiver Quantitative
Innoviva, Inc. (INVA) Stock Analysis: Biotech Powerhouse With 70% Upside Potential - DirectorsTalk Interviews
Innoviva Inc. (INVA) Pulls Back 0.95% to $20.77 as Traders Eye Key Support ZoneSwing Entry Signals - dars.gov.et
Finanzdaten der Innoviva Inc-Aktie (INVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):